Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Ajooni Biotech Limited
  6. News
  7. Summary
    AJOONI   INE820Y01021

AJOONI BIOTECH LIMITED

(AJOONI)
  Report
Delayed NSE India Stock Exchange  -  06:25:46 2023-01-30 am EST
5.650 INR   -1.74%
2022Ajooni Biotech : Newspaper Advertisements
PU
2022Ajooni Biotech : Outcome of committee meeting
PU
2022Ajooni Biotech : Reply to Clarification Sought- Financial Results
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ajooni Biotech : Press Release

12/07/2022 | 01:02am EST

AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

07/12/2022

To,

National Stock Exchange of India Ltd

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E)

Mumbai - 400051

Dear Sir / Madam,

Subject: Media Release "Ajooni Biotech Limited".

SYMBOL: AJOONI

Please find enclosed herewith announcement titled "Ajooni Biotech Ltd's Rs. 29.01

Crores Rights Issue Opens for Subscription on December 7"

You are requested to take the above information on records.

Thanking You,

Yours Truly,

For Ajooni Biotech Limited

JASJOT SINGH

Digitally signed by JASJOT SINGH

Date: 2022.12.07 11:07:12 +05'30'

Jasjot Singh

Managing Director

DIN: 01937631

______________________________________________________________________________________

Works: G.T. Road, Khanna- 141401 (Punjab) INDIA

Media Release

Ajooni Biotech Ltd's Rs. 29.01 Crores Rights Issue

Opens for Subscription on December 7

Rights Issue priced at Rs. 6 per - 30% discount to closing price on 6 December;

Rights Issue opens on December 7 and closes on December 15

Highlights:-

  • Funds raised through the issue will be used to meet working capital requirements of the company's business activities, fund company's expansion plans and general corporate purposes
  • The rights entitlement ratio for the proposed rights issue is 29:30; 29 rights equity shares of face value of Rs. 2 each for every 30 equity shares of Rs. 2 each held by the equity shareholders
  • Company had fixed November 25 as the record date for the purpose of determining the equity shareholders entitled to receive the rights entitlement in the rights issue
  • Company launched it's IPO on NSE Emerge platform in Dec 2017 & migrated to the main board of
    NSE in May 2021
  • For FY22, company reported sales of Rs. 74.04 crore - rise 46% Y-o-Y, EBITDA rise 87% Y-o-Y to Rs. 3.08 crore and Net Profit rise 183% Y-o-Y to Rs. 1.05 crore
  • Ajooni Biotech Ltd became the first Indian Animal Feed manufacturing company to get ZED certification from Ministry of Micro, Small & Medium Enterprises, Govt of India in November 2022

Mumbai, 6 December 2022: Ajooni Biotech Ltd(NSE - AJOONI) - One of the leading companies in the animal healthcare solutions and animal feed supplements is schedule to open its Rs. 29.01 crore rights issue on December 7, 2022. The funds raised through the issue will be utilised to meet the working capital requirements to fund company's expansion plans, entering new geographies and for general corporate purposes. Right issue of the company are offered at a price of Rs. 6 per share - 30% discount to closing share price on December 6, 2022. Rights Issue closes on December 15, 2022.

The Company will issue 4,83,60,313 fully paid-up Equity Shares of face value of Rs. 2 each for cash at a price of Rs. 6 per Equity Share (including a premium of Rs. 4 per Equity Share) aggregating to Rs. 29.01 Crore. The Rights entitlement ratio for the proposed issue is fixed at 29:30 (29 equity shares of face value of Rs. 2 each for every 30 equity shares of Rs. 2 each held by the equity shareholders on the record date - November 25). Last date for On-market Renunciation of Rights Entitlements is December 9, 2022.

Commenting on the development, Mr. Jasjot Singh, Chairman and Managing Director, Ajooni Biotech Ltd said, "Company has taken important strategic initiatives in the recent past with a focus to expand production capacities, launching new products, adding more channel partners and working with more farmers. Our long-termfocus continues to be investing in growth through new product launch, expanding footprints. We have a dedicated focus is to leverage capabilities, to develop cost effective solutions to improve animal productivity and accomplish its vision of 'To be a world class Animal Health Care Company'. Proceeds of the issue will further strengthen company's balance sheet and help fund its expansion plans and strategic growth initiatives."

Company's Board of the directors on October 17, 2022 approved the issuance of equity shares by way of a rights issue to eligible equity shareholders for an amount not exceeding Rs. 30 Crore. Post the rights issue, total outstanding shares of the company should increase to 9,83,88,223 equity shares from 5,00,27,910 equity shares prior to the rights issue.

JASJOT SINGH

Digitally signed by

JASJOT SINGH Date: 2022.12.07 11:09:12 +05'30'

Established in the year 2010, Ajooni Biotech Ltd has emerged as one of the leading animal healthcare solutions companies dedicated to improving the productivity of Dairy farmers and sustainably increase livestock yields. Company offers a wide range of products including Quality Cattle feed, Cattle feed Chips, Camel Feed, Cotton Oil Cake, Mustard Oil Cake and wide range of Feed supplements to cover the entire life-cycle of an animal. Company has two state-of-the-art manufacturing facilities with a cumulative Animal feed production capacity of 60,000 MTPA and liquid supplements capacity of 30 lakh Litres per annum. Company is currently working with more than 10,000 farmer families in seven states of Northern India and plans to grow nationally. Ajooni is also ISO and GMP certified company, manufacturing ISI mark Cattle Feed.

In November 2022, Ajooni Biotech Ltd became the first Indian Animal Feed manufacturing company to get ZED certification (Zero Effect Zero Defect) from Ministry of Micro, Small & Medium Enterprises, Govt of India. The Company is Registered with Department of Dairy Development, Govt of Punjab (India) and India's first GMP certified Cattle feed company with ISO 9001:2015. The company is registered with Bureau of Indian Standards (BIS) and manufacturing ISI Mark Animal feed. The Company is among main suppliers to leading companies like IFFCO Kisan, Mother Dairy, Paras Dairy & Saahaj Dairy.

The Indian animal feed market reached a value of Rs. 873.7 billion in 2021. Looking forward, the market is projected to reach Rs. 1493.8 billion by 2027, exhibiting at a CAGR of 9.6% during 2022- 2027. (Source - www.researchandmarkets.com, International Feed Industry Federation, Food & Agriculture Organization (FAO) of the United Nations). As per data from 20th Livestock Census 2019, Ministry of Fisheries, Animal Husbandry & Dairying, India has the world's largest number of livestock animals with 536 million along with large population of cattle and buffaloes which is estimated at more than 125 million milch cows and buffaloes.

For FY 22, Company reported sales of Rs. 74 crore - growth of 46% as against sales of Rs. 50.8 crore in FY21, EBITDA grew 88% to Rs. 3.08 crore in FY22, Net Profit registered 183% rise during FY22 to Rs. 1.05 crore. Company has achieved strong CAGR of 23% in Sales and 37% in Net Profit and 65% in EBITDA during the last 3 years with an improving return ratios. Promoter Group holding in the company is 67.35% as on 30 Sep 2022.

Company came up with it's IPO on NSE Emerge platform in December 2017 & migrated to the main board of NSE in May 2021. On 7 October 2022, there has been a stock split from Rs. 10 per equity share to Rs. 2 per equity share.

Robust Financial Performance over the last 5 years

Company has reported robust financial performance over the last 5 years. Sales has grew at a CAGR of 21% to Rs. 74 Crore in FY22 from Rs. 28.5 Crore in FY17. EBITDA and Net Profit too have maintain strong 30% plus CAGR during 5 years from FY17 to FY22.

Year

Sales

EBITDA

Net Profit

FY22

74.04

3.08

1.05

FY17

28.53

0.67

0.28

5 Year CAGR

21.1%

35.6%

30.3%

(in Rs. Cr)

Company executes first Export Order

With an objective to expand AJOONI Brand in global markets, company has executed its first export order for supply of Ajooni Cattle feed to Nepal after successful field trails in hilly country. Company has developed a unique product suitable to the specific feed requirements of animal species of the semi hilly areas of Nepal; Bhutan to achieve optimal nutrition, gut health and pathogen control of livestock while maximizing the profitability of Dairy farmers of these countries.

Company is also exploring all the possibilities to penetrate its marketing network to international markets of African Continent, South Asia and Middle East markets. You are requested to take the above information on records.

JASJOT SINGH

Digitally signed by

JASJOT SINGH Date: 2022.12.07 11:08:50 +05'30'

Disclaimer

Ajooni Biotech Ltd. published this content on 07 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2022 06:01:05 UTC.


ę Publicnow 2022
All news about AJOONI BIOTECH LIMITED
2022Ajooni Biotech : Newspaper Advertisements
PU
2022Ajooni Biotech : Outcome of committee meeting
PU
2022Ajooni Biotech : Reply to Clarification Sought- Financial Results
PU
2022Ajooni Biotech : Letter of Offer (Final Offer Document filed with Stock Exchanges)
PU
2022Ajooni Biotech : Press Release
PU
2022Galaxy Vitacare Private Limited, Symbiosis Pharmace..
CI
2022Ajooni Biotech : Record Date
PU
2022Ajooni Biotech Limited Reports Earnings Results for the Second Quarter and Six Months E..
CI
2022Ajooni Biotech : Outcome of committee meeting
PU
2022Ajooni Biotech : Record Date
PU
More news
Financials
Sales 2022 740 M 9,08 M 9,08 M
Net income 2022 10,5 M 0,13 M 0,13 M
Net Debt 2022 51,8 M 0,63 M 0,63 M
P/E ratio 2022 64,2x
Yield 2022 -
Capitalization 495 M 6,07 M 6,07 M
EV / Sales 2021 0,72x
EV / Sales 2022 0,98x
Nbr of Employees 77
Free-Float 32,7%
Chart AJOONI BIOTECH LIMITED
Duration : Period :
Ajooni Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AJOONI BIOTECH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Ramandeep Singh Independent Non-Executive Director
Simmi Chabbra Independent Director
Gursimran Singh Chief Executive Officer